Zai Lab Limited (NASDAQ:ZLAB) Receives $161.71 Average Price Target from Analysts

Zai Lab Limited (NASDAQ:ZLABGet Rating) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $127.25.

Several equities analysts have recently issued reports on the company. Macquarie assumed coverage on Zai Lab in a research note on Friday, January 21st. They issued an “outperform” rating and a $64.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on Zai Lab from $136.00 to $112.00 and set an “overweight” rating for the company in a research note on Monday, April 4th. SVB Leerink decreased their target price on Zai Lab from $194.00 to $102.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. Finally, Zacks Investment Research upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Thursday, April 7th.

In other Zai Lab news, Director William Lis sold 1,926 shares of the business’s stock in a transaction that occurred on Thursday, January 20th. The stock was sold at an average price of $53.40, for a total value of $102,848.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director John D. Diekman sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 4th. The shares were sold at an average price of $50.17, for a total value of $50,170.00. The disclosure for this sale can be found here. 6.26% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. WealthPLAN Partners LLC increased its holdings in shares of Zai Lab by 0.4% in the third quarter. WealthPLAN Partners LLC now owns 39,543 shares of the company’s stock valued at $2,787,000 after purchasing an additional 150 shares during the period. Penserra Capital Management LLC increased its holdings in shares of Zai Lab by 13.6% in the third quarter. Penserra Capital Management LLC now owns 1,585 shares of the company’s stock valued at $167,000 after purchasing an additional 190 shares during the period. Vident Investment Advisory LLC increased its holdings in shares of Zai Lab by 9.3% in the third quarter. Vident Investment Advisory LLC now owns 2,379 shares of the company’s stock valued at $251,000 after purchasing an additional 202 shares during the period. Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of Zai Lab by 1.1% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 22,646 shares of the company’s stock valued at $2,387,000 after purchasing an additional 247 shares during the period. Finally, Shell Asset Management Co. increased its holdings in shares of Zai Lab by 1.5% in the fourth quarter. Shell Asset Management Co. now owns 20,962 shares of the company’s stock valued at $1,317,000 after purchasing an additional 300 shares during the period. 66.97% of the stock is currently owned by institutional investors and hedge funds.

Shares of ZLAB traded down $0.24 during midday trading on Friday, hitting $44.41. The company had a trading volume of 251,298 shares, compared to its average volume of 686,518. The company’s 50-day simple moving average is $45.77 and its 200-day simple moving average is $65.16. The firm has a market capitalization of $4.28 billion, a P/E ratio of -5.81 and a beta of 1.20. Zai Lab has a 1 year low of $25.74 and a 1 year high of $181.92.

Zai Lab Company Profile (Get Rating)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.

Read More

Analyst Recommendations for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.